BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Analysts have given BridgeBio an average recommendation of "Moderate Buy" from 25 firms (24 buy, 1 sell), with a 12‑month consensus price target of about $87.38.
• Significant insider activity: CEO Neil Kumar sold 40,000 shares at $74.62 and Director Andrea Ellis sold 64,921 shares, with insiders selling 237,084 shares valued at $16.63M over the last 90 days while still owning 18.20% of the stock.
• Recent results and stock metrics: BBIO reported a quarterly loss of $1.00 EPS (missing estimates) and $154.18M revenue (up 2,521% YoY), trades in a 52‑week range of $31.77–$84.94, has a $14.21B market cap, and analysts forecast -2.07 EPS for the fiscal year.

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) have been given an average recommendation of "Moderate Buy" by the twenty-five ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and twenty-four have assigned a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $87.3810.

BBIO has been the topic of several research analyst reports. Mizuho boosted their target price on BridgeBio Pharma from $91.00 to $106.00 and gave the company an "outperform" rating in a research note on Wednesday, March 18th. JPMorgan Chase & Co. boosted their target price on BridgeBio Pharma from $89.00 to $94.00 and gave the company an "overweight" rating in a research note on Tuesday, March 10th. Barclays restated an "overweight" rating on shares of BridgeBio Pharma in a research report on Tuesday, March 10th. Wells Fargo & Company lifted their price target on BridgeBio Pharma from $88.00 to $98.00 and gave the company an "overweight" rating in a research report on Friday, February 13th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of BridgeBio Pharma in a research report on Wednesday, January 21st.

Insider Activity at BridgeBio Pharma

In related news, CEO Neil Kumar sold 40,000 shares of BridgeBio Pharma stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $74.62, for a total transaction of $2,984,800.00. Following the sale, the chief executive officer directly owned 615,686 shares in the company, valued at $45,942,489.32. The trade was a 6.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Andrea Ellis sold 64,921 shares of BridgeBio Pharma stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $64.87, for a total value of $4,211,425.27. Following the sale, the director owned 18,589 shares in the company, valued at $1,205,868.43. This represents a 77.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 237,084 shares of company stock valued at $16,634,419 over the last ninety days. Insiders own 18.20% of the company's stock.

Institutional Investors Weigh In On BridgeBio Pharma

Several hedge funds have recently made changes to their positions in BBIO. Jones Financial Companies Lllp bought a new stake in shares of BridgeBio Pharma during the first quarter valued at approximately $35,000. First Trust Advisors LP boosted its holdings in BridgeBio Pharma by 200.4% in the second quarter. First Trust Advisors LP now owns 263,693 shares of the company's stock worth $11,386,000 after acquiring an additional 175,918 shares in the last quarter. Baird Financial Group Inc. boosted its holdings in BridgeBio Pharma by 1.8% in the second quarter. Baird Financial Group Inc. now owns 42,057 shares of the company's stock worth $1,816,000 after acquiring an additional 731 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new stake in BridgeBio Pharma in the second quarter worth $1,650,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in BridgeBio Pharma by 2.4% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 95,326 shares of the company's stock worth $4,132,000 after acquiring an additional 2,206 shares in the last quarter. 99.85% of the stock is currently owned by institutional investors.

BridgeBio Pharma Stock Performance

BBIO opened at $73.28 on Friday. BridgeBio Pharma has a 52-week low of $31.77 and a 52-week high of $84.94. The stock has a market capitalization of $14.21 billion, a PE ratio of -19.39 and a beta of 1.09. The stock's 50 day moving average price is $71.46 and its 200-day moving average price is $70.50.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last posted its earnings results on Tuesday, February 24th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.25). The firm had revenue of $154.18 million during the quarter, compared to analysts' expectations of $150.71 million. During the same quarter in the previous year, the business earned ($1.40) earnings per share. The business's revenue for the quarter was up 2521.2% on a year-over-year basis. Research analysts forecast that BridgeBio Pharma will post -2.07 EPS for the current fiscal year.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.